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investigating the impact of antiretroviral
treatment on the partnerships and sexual
behaviour of HIV-infected individuals in rural
KwaZulu-Natal, South Africa
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Abstract
Background: Diagnosed HIV-infected people form an increasingly large sub-population in South Africa, one that
will continue to grow with widely promoted HIV testing and greater availability of antiretroviral therapy (ART). For
HIV prevention and support, understanding the impact of long-term ART on family and sexual relationships is a
health research priority. This includes improving the availability of longitudinal demographic and health data on
HIV-infected individuals who have accessed ART services but who are not yet ART-eligible.
Design and methods: The aim of the study is to investigate the impact of ART on family and partner relationships,
and sexual behaviour of HIV-infected individuals accessing a public HIV treatment and care programme in rural South
Africa. HIV-infected men and women aged 18 years or older attending three clinics are screened. Those people
initiating ART because they meet the criteria of WHO stage 4 or CD4 ≤ 200 cells/μL are assigned to an ‘ART initiator’
group. A ‘Monitoring’ group is composed of people whose most recent CD4 count was >500 cells/μL and are therefore,
not yet eligible for ART. During the four-year study, data on both groups is collected every 6 months during clinic visits,
or where necessary by home visits or phone. Detailed information is collected on social, demographic and health
characteristics including living arrangements, past and current partnerships, sexual behaviour, HIV testing and disclosure,
stigma, self-efficacy, quality of family and partner relationships, fertility and fertility intentions, ART knowledge and
attitudes, and gender norms. Recruitment for both groups started in January 2009. As of October 2010, 600 participants
have been enrolled; 386 in the ART initiator group (141, 37% male) and 214 in the Monitoring group (31, 14% male).
Recruitment remains open for the Monitoring group.
Discussion: The data collected in this study will provide valuable information for measuring the impact of ART on
sexual behaviour, and for the planning and delivery of appropriate interventions to promote family and partner
support, and safe sexual behaviour for people living with HIV in this setting and elsewhere in sub-Saharan Africa.
Background
Diagnosed HIV-infected people form an increasingly
large sub-population in South Africa, one that will con-
tinue to grow with widely promoted HIV testing and
greater availability of antiretroviral therapy (ART).
Factors that have been identified as being associated
with unsafe sexual behaviours in HIV-infected people
include: age, income [1], depression [2], drug and alco-
hol use [3,4], low self-efficacy [5], attitudes to condoms
[1] and suprainfection, conception [6], duration of rela-
tionship [7], intimate partner violence [8,9], perceived
stigma, and disclosure to family and partner(s) [10-12].
The relative influence of risk factors may change over
time in a population of HIV-infected people, for exam-
ple, as a result of changes in sexual behaviour norms.
The determinants of unsafe sexual behavior can also
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change over time for a HIV-infected person depending
on factors including the length of time since HIV diag-
nosis, the quality of counselling and support, and the
HIV status of their partner. Many HIV-infected people
are in HIV discordant couples [13] for whom practicing
safer sex consistently over a long period may be chal-
lenged by numerous factors including emotional and
sexual intimacy issues, poor communication, and stres-
ses including concerns about family disclosure and
childbearing [2,14-16].
For HIV-infected people, experiences associated with
morbidity and HIV treatment may have important influ-
ence on their family and partnering relationships, and
sexual behaviours. ART reduces infectivity, however, it
also increase the duration of potential infectiousness by
reducing morbidity and mortality, and may also result in
risk compensation [17]. Thus, efforts to promote safer
sex (for example, reduction of concurrent partnerships,
reduction of the number of partnerships, condom use,
abstinence) in people receiving HIV treatment and their
partners remains an important public health goal.
Several direct and indirect effects of ART have been
identified on psycho-sexual functioning [18-20]. Side
effects, in particular lipodystrophy, may result in sexual
dysfunction [21]. Low self-efficacy is associated with poor
adherence [22-24], as well as, a higher risk of unsafe sex-
ual behaviours [25]. However, there is a pressing need to
monitor sexual risk behaviours of HIV-infected people
over time to measure the full extent of long-term ART
on sexual behaviour and HIV transmission [26-28]. Stu-
dies in Europe, US and Africa have reported that HIV-
infected individuals receiving ART do not have increased
sexual risk behaviour [29-34]. Yet, in order to inform sec-
ondary prevention efforts, greater knowledge about
family and partnering contexts, issues related to stigma
and HIV disclosure, and characteristics associated with
unsafe sexual behaviours of HIV-infected people is
needed. This information is especially important in sub-
Saharan Africa where the HIV epidemic has been most
severe and public access to HIV treatment is relatively
recent compared to developed countries.
A group of HIV-infected people little studied with
respect to their sexual behavior are HIV-infected indivi-
duals who have accessed ART services but who are not
yet ART-eligible. This group are difficult to prospec-
tively study as they have high attrition from HIV clinics
[35], and the period of follow-up after diagnosis of HIV
may be short as individuals initiate ART or die. None-
theless it is important to learn more about this group
for two reasons. First, HIV prevention strategies may
need to be specifically tailored for people who know
their HIV positive status but do not yet require treat-
ment. Second, this group provides an appropriate
comparison for studying the impact of ART initiation
on sexual behaviour.
In Africa, the few studies that have sought to measure
the impact of ART initiation on sexual behavior vary
widely in their design. In a study by Bunnell et al in
Uganda, there was no comparison group with which to
compare the observed changes in sexual behaviour in
HIV-infected people receiving ART [34]. One South
African study used two separate cross-sectional samples
of HIV-infected people waiting to start ART to control
for sexual behaviour trends in a cohort of people initiat-
ing ART [33]. A limitation of repeated samples is that
each sample may differ in important ways that are
unmeasured. Consequently, a lack of difference in sexual
behaviours between the two cross-sectional samples may
be an artifact of the sampling process. Other cohort stu-
dies in Africa have compared sexual behavior pre-ART
with sexual behavior reported after ART initiation
[31,32]. In these studies, the same individual may there-
fore contribute to pre- and post-ART exposure groups.
A limitation of this approach is that for each individual,
the pre-ART period will always be earlier than their
post-ART period, and thus, any secular changes in sex-
ual behaviours during the period of study might erro-
neously be interpreted as an impact of ART. Adjusting
for time in the cohort [31] or conducting sensitivity ana-
lyses [32] provides information with which to assess
whether study results may have been influenced by fac-
tors other than ART. In our study of long-term sexual
behaviors of participants in a rural ART programme in
South Africa, we used a different study design; that of
prospectively observing sexual behavior of pre- and
post-ART groups simultaneously. Our control group
consists of people not yet eligible for ART who are fol-
lowed longitudinally at the same time as a group start-
ing ART.
Aims and objectives
This study aims to investigate the impact of antiretro-
viral treatment (ART) on family and partner relation-
ships, and sexual behaviour of HIV-infected individuals
in rural South Africa by following a prospective cohort
of HIV-infected individuals in the Hlabisa sub-district of
Umkhanyakude in northern KwaZulu-Natal, South
Africa. The sample consists of people initiating ART
and those not yet eligible for ART (monitoring group).
This is a joint study between the Africa Centre for
Health and Population Studies which is part of the
University of Kwazulu-Natal (UKZN), the South African
Human Sciences Research Council (HSRC) and the
London School of Hygiene and Tropical Medicine.
The study is funded by the Wellcome Trust through a
fellowship award to McGrath.
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The specific objectives of this study are to
1. Describe sexual behaviour and partnership atti-
tudes and partner change over a three year period
among ART initiators and those being monitored
for ART
2. Explore which clinical and psychosocial factors are
associated with sexual behaviour change among ART
initiators and those being monitored for ART
3. Explore how clinical and psychosocial factors
change over time among ART initiators and those
being monitored for ART
4. Study whether sexual behaviour changes as people
transition from pre- and early to longer term
treatment
Target population
The target population is HIV-infected individuals who
are resident in the Africa Centre Demographic Surveil-
lance Area (ACDSA) in the rural Umkhanyakude district
of KwaZulu-Natal, South Africa, and accessing ART
clinics for HIV care. Since 2000, the Africa Centre
Demographic Information System (ACDIS) has collected
longitudinal social, demographic and health data from a
Zulu speaking population of approximately 86,000 [36]
(see http://www.africacentre.ac.za). This population has
experienced a severe HIV epidemic, with prevalence in
2003/4 peaking at 50.9%, 95%CI (47.2-54.6) among resi-
dent females aged 25-29 years and 43.5% (38.0-49.0)
among resident males aged 30-34 years [37], and contin-
ued high crude HIV incidence rates per 100 person-
years of 3.8 (95% CI, 3.2-4.6) among women aged 15-49
years and 2.3 (95% CI, 1.8-3.1) among men aged 15-54
years [38]. The study area has a decentralized pro-
gramme of HIV treatment and care is delivered through
a network of 17 primary health care clinics in the Hla-
bisa subdistrict of Umkhanyakude [39]; 6 of these clinics
are located within the ACDSA. The programme, which
started in late 2004, is a partnership between the local
Department of Health and the Africa Centre for Health
and Population Studies, and follows the South African
Comprehensive HIV and AIDS Care, Management and
Treatment Plan, (see Houlihan et al, 2010, for details of
Programme procedures for HIV diagnosis, ART eligibil-
ity, treatment regimens and follow-up [40]). The Africa
Centre has established research facilities alongside the
government ART clinics.
Routine data collected at the clinics include informa-
tion about ART initiation, ART combination prescribed,
vital status, TB status and treatment, pregnancy, viral
load and CD4. This information is entered into a data-
base developed and maintained at the Africa Centre
(ART Evaluation and Monitoring Information System,
or ARTemis), and is updated with each repeated visit to
the clinic. Laboratory results (CD4 cell count and HIV
load) are also regularly imported into ARTemis from
the laboratory at the local district hospital or from clinic
records. The ACDIS database provides longitudinal
demographic information including pregnancy histories
for women, household living arrangements, mobility and
socioeconomic status. It is possible to link individuals
who are in ARTemis with the ACDIS databases if they
are a member of a household in the ACDSA, through
an individual’s South African identity number [39].
Methods/Design
HIV-infected men and women, accessing the HIV treat-
ment and care programme at any of the three busiest
ART clinics in the ACDIS surveillance area, who are
aged 18 years or older and resident within the ACDSA
are potentially eligible for this study. In addition, indivi-
duals must be willing to participate in a study interview
at the clinic every 6 months; be willing to answer ques-
tions about themselves, their relationships and sexual
activity; and be prepared to provide phone contact
details to permit study staff to contact them for tracking
and queries.
This study follows two groups over time (1) those
starting ART (ART initiators) and (2) those who are not
yet eligible for treatment (Monitoring group). Indivi-
duals who are eligible to initiate ART (i.e. WHO stage 4
or CD4 ≤ 200 cells/μL), are assigned to the ART initia-
tor group. If individuals eligible for the study have a
CD4 count >500 cells/μL from a recent CD4 test, they
are assigned to the Monitoring group. A cut-off of
CD4>500 cells/μL was chosen because we wished to col-
lect repeated measures of this group over time before
they initiate treatment, and prior studies suggest that
the median time from presenting with a count between
500 and 650 cells/μL to having a count <350 cells/μL is
2.5 years, with approximately 75% and 90% having <350
cells/μL within 5 and 8 years, respectively [41]). Indivi-
duals with CD4 between 200 cells/μL and 500 cells/μL
are excluded from the study because they are likely to
start ART in the short-term and would contribute lim-
ited person-years of follow-up to the Monitoring group,
particularly relevant in light of any changes in the South
African programme guidelines for ART eligibility. Any
individual who has previously received ART and
defaulted or is currently established on ART (for ≥2
weeks), planning to leave the area in the next 12 months,
or pregnant at the time of recruitment, are also
excluded from the study. Pregnant women are excluded
because sexual activity is often different during preg-
nancy and CD4 counts are known to decline during
pregnancy [42], providing unsuitable baseline data. If a
female participant in the study becomes pregnant during
follow-up, they remain in the study.
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Sample size calculations
Separate sample sizes were calculated for the two
groups. The primary outcomes of interest are changes
in sexual behaviour that occur by 2 years of follow-up.
Current condom use was used for these calculations as
an available indicator of change in sexual behaviour. In
2005, 16% of women aged 15-49 in ACDIS reported
current use of condoms. Using this estimate as a base-
line, and wishing to detect an increase in condom use to
30% at 2 years, with 80% power and alpha level of 0.05,
requires 142 women. Conservatively assuming that 20%
would be lost to follow-up by 2 years, the enrolment
target was 178 women for each group. Men’s reported
current use of condoms in 2005 was higher, with 30%
reporting condom use at last sex. Wishing to detect an
increase in condom use from 30% to 50% at 2 years,
with 80% power and alpha level of 0.05, requires
96 men. Conservatively assuming 20% would be lost to
follow-up by 2 years, the enrolment target was 120 men
for each group. Thus, our sample size for each group
was 300 (178+122), with a target of 40% men. A recruit-
ment target of 100 of each group (ART initiators vs
monitored) was set for each of the 3 study clinics The
protocol was written to include a review of loss to fol-
low-up of both groups before recruitment closed, and
allowed for an increase in sample size, if needed, to
maintain study power.
Recruitment procedures
A general introduction to the study is given each morn-
ing by study staff in the waiting room at the clinic,
explaining why the study is taking place, what participa-
tion entails, what the anticipated benefits are and
answering any queries about the study. Leaflets describ-
ing the study are also handed out. Additional study
introductions are targeted to patients presenting for
CD4 testing and they are asked to present themselves to
a study staff member again when they return to the
clinic two weeks later for their CD4 results if they are
interested in joining the study.
When an individual receives their CD4 result at the
clinic and, if they indicate that they are interested in
participating in the study, the study staff member allo-
cates a study number which is used on all forms,
screens the individual using the screening checklist and,
if eligible, they are led through the study information
sheet and informed consent process.
In an effort to reduce the length of the interview at
each visit, participants are asked during the informed
consent process to separately consent to their study data
being linked to their routine clinical data in ARTemis,
and the ACDIS data. If participants do not agree to the
linking, enrolment into the study is unaffected, and
additional questions are asked at a follow-up visit to col-
lect these data.
Patients are only enrolled after they have given fully
informed consent in writing. No financial remuneration
is offered to participants. Once enrolled, a baseline
questionnaire is administered in a private room by a
study staff member. The questionnaire is conducted
while the participant is waiting to see ART clinic staff.
Patients usually have to wait at ART clinic for several
hours and, based on previous experience of working in
the clinic, we are able to make provisions to ensure the
participant does not lose their place in the clinic queue
while participating in the study. Non-study staff working
in the clinic are familiar with the study purpose and
procedures and help facilitate the study by making
potential participants aware of the study and by direct-
ing participants to the study room on busy days.
Individuals who are initiating treatment have three
counseling sessions at the clinic before they receive
ART. These visits to the clinic provide additional oppor-
tunities to enroll eligible ART initiators if they are not
ready to enroll on the day they receive their CD4 result.
Follow-up procedures
Follow-up for both the ART initiator group and the
Monitoring group is scheduled for every 6 months, for a
maximum of 8 follow-up visits over the four-year study
period. The ART initiator group is interviewed at their
closest monthly visit for treatment collection, and the
Monitoring group is interviewed during their 6 monthly
visit for CD4 testing.
A month before each scheduled study visit, partici-
pants in the ART initiator group are reminded of the
planned interview by study staff when they collect their
treatment at the clinic. If the participant is not seen at
the clinic, they are contacted by cell phone.
For the Monitoring group, at each study visit, an
appointment is set for the next scheduled visit 6 months
later and an appointment card is completed and taken
home by the participant. A week before the appoint-
ment date, the study staff reminds the participant by
phone of their need to test for CD4 again, even if they
feel well, and of their related upcoming study visit.
Tracking procedure
During the baseline interview, the contact details of the
participant and at least one other person who is likely
to know the whereabouts of the participant are
recorded. Detailed directions to the participant’s resi-
dence are taken, and the names of the school, church
and shop nearest to their current residence are also
noted. In addition, details of an alternative household,
defined as place they might visit when they are not
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staying at their usual residence, are also taken. These are
updated on each subsequent contact.
Every effort is made by study staff to minimize loss to
follow-up. If an individual misses their study appoint-
ment, phone contact is attempted. Home visits are made
to investigate the status of defaulters, if phone contact
has not been possible, and consent for home visits has
been given during the informed consent process. If the
individual moves out of the area, or is too busy to come
to the clinic because they are temporarily away or work-
ing, the study team tries to arrange an appointment at a
place convenient for the participant, or administers the
questionnaire by phone.
Staffing
The research assistants administering the questionnaires
have specialized training and experience in asking sensi-
tive questions, probing for consistency and clarity, tran-
sitioning from one section to another and keeping
interviewees engaged; they also have strong HIV and
ART counseling skills. Study staff are trained to follow
Africa Centre standards and guidelines to protect confi-
dentiality. Clinic staff cooperate with the study by facili-
tating participants stepping out of the ART clinic queue
for interview, informing potential participants of the
study and directing them to our study staff member.
Data collection instruments
Baseline
The questionnaire sought detailed information on socio-
demographic characteristics (age, sex, marital history);
socio-economic circumstances (employment, income,
receipt of grants, household assets); religion; HIV testing
history and disclosure of HIV status; stigma; self-
efficacy; partnership history and current sexual beha-
viour (including condom use, concurrency and multiple
partnerships); fertility and fertility intentions with cur-
rent main partner and the quality of that relationship
including questions about communication, conflict, sta-
bility, identity and commitment; knowledge of and atti-
tudes to ART; social capital and gender norms. Other
gender-specific information is also collected, specifically,
current use of contraception among women, and cir-
cumcision and vasectomy status among men. Where
possible, questions that had previously been adminis-
tered in ACDSA, in South Africa, or elsewhere in Africa
were used (eg. questions about fertility intentions [43]
and social capital [44,45]). In the case of psychological
scales, we adapted scales to measure gender norms [46]
and stigma [47], and the scale items were administered
during interviews with 3 options for an answer: agree,
no opinion, and disagree. Copies of the questionnaire
are available by request from NM.
Interviews are conducted in Zulu, therefore all ques-
tionnaires and informed consent documents were trans-
lated into Zulu. Translation and back-translation
procedures were used to ensure the equivalence of the
meaning of questions in English and Zulu. The ques-
tionnaire for the most part contains closed questions,
but there are some open questions as well. Question-
naires were piloted extensively during the development
of the study using focus groups with Africa Centre staff,
and revised in the light of feedback and comments
Follow-up
The follow-up questionnaires collect identical informa-
tion to the baseline except to explore whether the indivi-
dual’s circumstances or experiences have changed in the
period since the last interview. For stigma, gender norms,
fertility intentions with current main partner and the
quality of that relationship, status observations rather
than changes since last interview are collected. In addi-
tion, the follow-up questionnaire collects information on
substance use (alcohol and substance use), health-seeking
behaviour and ART adherence, disclosure of ART and
side-effect questions for those who are on ART.
To aid follow-up interviews, a summary of previously
reported key information is extracted from the database
and used to prepare the form for the upcoming visit.
This has assisted in further building rapport during fol-
low-up interviews and has enhanced reliability of reports.
Furthermore, the need for respondents to answer com-
plex, inter-related questions that can be cross-checked by
the interviewer immediately encourages frank responses.
Although face-to-face interviews about socially sensitive
information are always subject to some social desirability
bias in reporting, the interviews are conducted to encou-
rage openness in a non-judgmental confidential setting.
That this is successful is indicated by the many partici-
pants who contact study staff between study visits, by
phone and in person, particularly those who are attend-
ing the clinic monthly to collect their ART.
Analysis plan
To assess factors associated with being sexually active
and changes in sexual activity longitudinally, we will
conduct participant-level analyses (i.e. the unit of analy-
sis will be the enrolled participant). Multivariable logis-
tic regression models will be used to identify factors
associated with sexually activity at baseline, and com-
pare sexual activity at baseline with follow-up. Attitudes,
indicators of relationship quality and, individual charac-
teristics will be examined as possible modifiers of sexual
behaviour change over time. The extent to which these
factors change with the expanding availability of ART
or with treatment duration will also be investigated.
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ART side effects data will help to separate physical fac-
tors from psychosocial reasons for changes in sexual
behaviour. Analyses will be stratified by gender and the
interaction between gender and age will be explored.
We will also conduct multivariable sexual partner-
level analyses (i.e. the unit of analysis will be a sexual
partner of a study participant). Rates of unsafe sex will
be compared using a Poisson regression model. Charac-
teristics of the partnership will be investigated as poten-
tial modifiers of the unsafe sex rate. Multiple partners of
the same study participant will be included as separate
units of analysis, and repeated measures will be reflected
in the covariance structure for the models.
Table 1 shows the primary outcomes of interest in the
study. These outcomes were chosen because previous
work has shown that they are associated with the effi-
ciency of HIV transmission per contact and exposure of
susceptible persons to infected persons, as noted in the
table [48]. The two study groups will be compared with
respect to each outcome in order to estimate the impact
of ART on that outcome.
Community entry and research ethics approval
Africa Centre policy requires that all new research projects
are introduced to the community by the Africa Centre’s
community liaison office. Our study was introduced to the
Africa Centre’s Community Advisory Board (AC CAB) for
their input and approval on May 29th 2008. The AC CAB,
which meets on a regular basis, consists of about 40 mem-
bers nominated by the community. In addition, the study
protocol was presented to the Medical Manager of Hlabisa
Hospital on June 3rd, 2008, and to Hlabisa Hospital Man-
agement in their management meeting on June 9th, 2008.
All components of the study (ref BF083/08), including the
linking of ARTemis data to the population-based ACDIS
data (ref E134/06) were given approval by the University
of KwaZulu-Natal ethics committee. Approval for the
study protocol and associated information sheets, consent
forms and questionnaires was also received from the
Office of the Principal Technical Advisor on Research, in
the provincial Department of Health in Pietermaritzburg,
and from the London School of Hygiene and Tropical
Medicine ethics committee (ref 5413).
Discussion
Study Progress: Recruitment phase
Recruitment for both groups started in January 2009. As of
October 2010, 600 individuals have been enrolled; 386 in
the ART initiator group (141, 37% male) and 214 in the
Monitoring group (31, 14% male); recruitment only
remains open for the Monitoring group. As expected,
recruitment among the Monitoring Group compared to
Table 1 Study Outcomes and their definitions
Outcome
(at 2 years)1
Definition of outcome Factor influencing
efficiency of
transmission
Factor reflecting exposure of
susceptible to infected
persons
Proportion of sexual
acts involving a
condom
Number of sex acts protected by a condom throughout divided by
the number of sex acts in the last month2
√
Condom use at last
sex
At last sex, use of condom throughout √
Unsafe sex Inconsistent condom use with a HIV-negative or unknown
serostatus partner in the past 6 months
√ √
Sexually active One or more sex acts in the last month √
Frequency of sex acts
within each
partnership
The number of sex acts with each partner in the last month √
Rates of acquisition
of new sex partners
The number of new partnerships in the last 6 months divided by
the person years of follow-up in the last 6 months
√
Rates of dissolution
of existing
partnerships
The number of partnerships ended in the last 6 months divided by
the person years of follow-up in partnership in the last 6 months
√
Frequency of
concurrent
partnerships
Number of overlapping sexual partnerships in which sexual
intercourse with one partner occurs between two acts of
intercourse with another partner3
√
Abstinence No sexual intercourse during the past 6 months √
1 Analyses of these outcomes will also be conducted at earlier time-points.
2 Information is collected in the last month; however, if there was no sex in the last month, the questions are asked about the last 3 months; and if no sex in the
last 3 months, the questions are asked about the last 6 months.
3 UNAIDS Reference Group on Estimates, Modelling, and Projections: Working Group on Measuring Concurrent Sexual Partnerships. HIV: consensus indicators are
needed for concurrency. Lancet. 2010 Feb 20;375(9715):621-2.
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the ART initiator group is slower. It appears that the
majority of people presenting for CD4 counts at local
clinics are doing so because they are sick and therefore are
likely to have CD4 counts well below 500, the minimum
eligibility criteria for the Monitoring group. In addition,
the small number of men recruited to this group to date
appears to reflect the experience of the ART programme
more generally. In an analysis of all ART-naive adults pre-
senting with CD4 >200 cells/mm3 between Jan 1st and
Dec 31st 2007 in the Hlabisa HIV Treatment and Care
Programme, 83% were female [35].
To date, all participants have given consent to link
their data collected in this study with their routine ART
data and ACDIS data. Only one individual has refused
to consent to being visited at home. The baseline inter-
views take a median of 31 minutes (IQR: 25-38).
In April 2010, national ART programme eligibility cri-
teria were modified to allow all HIV-infected individuals
with TB (after they complete the intensive phase of TB
treatment), and pregnant women who have CD4 < 350,
to start ART, in addition to those who have a CD4 ≤
200 or are WHO stage IV. These changes in the pro-
gramme have not affected recruitment because the
majority of the ART initiator group had been recruited
prior to the introduction of these additional criteria, but
these changes may increase the proportion of the Moni-
toring group who initiate ART during the study.
As part of the study design, a ‘recent’ CD4 test was
defined as less than 21 days before enrollment. However,
this was found to be unreasonably restrictive given that
CD4 results are only available at the clinic 2 weeks after
testing (CD4 testing is performed centrally at Hlabisa hos-
pital for the ART programme), giving little time for poten-
tial participants to present for their CD4 results at the
clinic and be enrolled. Thus, the definition of ‘recent’ was
relaxed to allow enrollment within 8 weeks of a CD4 test.
Study Progress: Follow-up phase
As of October 8th, 2010, 542 of the enrolled individuals
(359 (66%) in ART initiator group) were expected to
have completed their 6 m visit. Overall, 485 (89%) had
been interviewed again with no difference according to
group (p = 0.51). In both groups, women were more
likely to have been re-interviewed than men (92% vs
84% in the ART initiator group and 92% vs 85% in the
Monitoring group respectively), although the difference
was only statistically significant among the ART initiator
group (p = 0.018).
In our study, we have tried to retain participants in
the study by interviewing them elsewhere or over the
phone if they do not return to the clinic. Seventy-three
percent (73%) of the 6-month interviews completed in
the ART initiator group were conducted at the clinic,
compared to 61% for the Monitoring group (p = 0.024).
Among those in the ART initiator group who were not
interviewed at the clinic for their 6-month study visit,
55% were interviewed by phone, 32% at home, 8% at
work and 5% elsewhere. Among those in the Monitoring
group who were not interviewed at the clinic for their 6-
month study visit, 43% were interviewed by phone, 46%
at home, 5% at work and 6% elsewhere. In contrast,
among individuals presenting for the first time to the
local programme with CD4 >500, 40% returned for
another CD4 test within 13 months, with a median time
to return of 232 days (IQR 154-313), and men were less
likely to return [35]. This suggests that our approach of
allowing follow-up interviews to be conducted by phone
is helpful for study retention.
Summary
This clinic-based study will allow us to follow longitud-
inally over 600 HIV-infected individuals receiving ART
and/or care in rural KwaZulu-Natal. The data collected
in this study will provide an opportunity to estimate the
impact of ART on sexual behaviour. In addition,
the study data will provide valuable information for the
planning and delivery of appropriate interventions to
promote family and partner support, and safe sexual
behaviour for people living with HIV not only in rural
KwaZulu-Natal but in other parts of sub-Saharan Africa.
Funding
The HIV treatment and care programme has received
generous support from the United States Agency for
International Development (USAID) and the President’s
Emergency Plan for AIDS Relief (PEPFAR) under the
terms of award no. 674-A-00-08-0001-00. The opinions
expressed herein are those of the authors and do not
necessarily reflect the views of USAID or the United
States Government. The Africa Centre is supported by a
core grant from the Wellcome Trust. Nuala McGrath
was supported by a Wellcome Trust fellowship (grant #
WT083495MA).
Author details
1London School of Hygiene and Tropical Medicine, London, UK. 2Africa
Centre for Health and Population Studies, University of KwaZulu-Natal,
Somkhele, South Africa. 3Human Sciences Research Council, Durban, South
Africa. 4UCL, Institute of Child Health, London, UK.
Authors’ contributions
NM led study design and writing. All authors contributed to study design
and drafting the manuscript. All read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 31 January 2011 Accepted: 19 February 2011
Published: 19 February 2011
McGrath et al. BMC Public Health 2011, 11:121
http://www.biomedcentral.com/1471-2458/11/121
Page 7 of 9
References
1. Reilly T, Woo G: Predictors of high-risk sexual behaviour among people
living with HIV/AIDS. AIDS Behav 2001, 5:205-217.
2. Tangmunkongvorakul A, Celentano DD, Burke JG, de Boer MA, Wongpan P,
Suriyanon V: Factors influencing marital stability among HIV discordant
couples in northern Thailand. AIDS Care 1999, 11:511-524.
3. Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S: Alcohol Use and
Sexual Risks for HIV/AIDS in Sub-Saharan Africa: Systematic Review of
Empirical Findings. Prev Sci 2007, 8:141-151.
4. Weiser SD, Leiter K, Heisler M, McFarland W, Percy-de Korte F,
DeMonner SM, Tlou S, Phaladze N, Iacopino V, Bangsberg DR: A
population-based study on alcohol and high-risk sexual behaviors in
Botswana. PLoS Med 2006, 3:e392.
5. Robins A, Dew M, Davidson L, Becker J, Kingsley L: Psychosocial factors
associated with risky sexual behaviour among HIV-seropositive gay men.
AIDS Education and Prevention 1994, 6:492.
6. Moore AR, Oppong J: Sexual risk behavior among people living with HIV/
AIDS in Togo. Soc Sci Med 2007, 64:1057-1066.
7. Guimaraes MD, Boschi-Pinto C, Castilho EA: Safe sexual behaviour among
female partners of HIV-infected men in Rio de Janeiro, Brazil. Int J STD
AIDS 2001, 12:334-341.
8. Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntryre JA, Harlow SD:
Gender-based violence, relationship power, and risk of HIV infection in
women attending antenatal clinics in South Africa. Lancet 2004,
363:1415-1421.
9. Wojcicki JM: “She drank his money": survival sex and the problem of
violence in taverns in Gauteng province, South Africa. Med Anthropol Q
2002, 16:267-293.
10. Simbayi LC, Kalichman SC, Strebel A, Cloete A, Henda N, Mqeketo A:
Disclosure of HIV status to sex partners and sexual risk behaviours
among HIV-positive men and women, Cape Town, South Africa. Sex
Transm Infect 2007, 83:29-34.
11. Kiene SM, Christie S, Cornman DH, Fisher WA, Shuper PA, Pillay S,
Friedland GH, Fisher JD: Sexual risk behaviour among HIV-positive
individuals in clinical care in urban KwaZulu-Natal, South Africa. AIDS
2006, 20:1781-1784.
12. Kalichman SC, Nachimson D: Self-efficacy and disclosure of HIV-positive
serostatus to sex partners. Health Psychol 1999, 18:281-287.
13. Lurie MN, Williams BG, Zuma K, Mkaya-Mwamburi D, Garnett GP, Sweat MD,
Gittelsohn J, Karim SS: Who infects whom? HIV-1 concordance and
discordance among migrant and non-migrant couples in South Africa.
AIDS 2003, 17:2245-2252.
14. Allen S: Why is fertility an issue for HIV-infected and at-risk women? J
Acquir Immune Defic Syndr 2005, 38(Suppl 1):S1-S3.
15. Kalichman SC, Rompa D, Luke W, Austin J: HIV transmission risk
behaviours among HIV-positive persons in serodiscordant relationships.
Int J STD AIDS 2002, 13:677-682.
16. Vandevanter N, Thacker AS, Bass G, Arnold M: Heterosexual couples
confronting the challenges of HIV infection. AIDS Care 1999, 11:181-193.
17. Cassell MM, Halperin DT, Shelton JD, Stanton D: Risk compensation: the
Achilles’ heel of innovations in HIV prevention? BMJ 2006, 332:605-607.
18. Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P:
Access to antiretroviral treatment and sexual behaviours of HIV-infected
patients aware of their serostatus in Cote d’Ivoire. AIDS 2003, 17(Suppl
3):S69-S77.
19. Florence E, Schrooten W, Dreezen C, Gordillo V, Nilsson SL, Asboe D,
Koitz G, Colebunders R: Prevalence and factors associated with sexual
dysfunction among HIV-positive women in Europe. AIDS Care 2004,
16:550-557.
20. Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G,
Finazzi R, de MI, Florence E, Dreezen C: Sexual dysfunction associated
with protease inhibitor containing highly active antiretroviral treatment.
AIDS 2001, 15:1019-1023.
21. Richardson D, Lamba H, Goldmeier D, Nalabanda A, Harris JR: Factors
associated with sexual dysfunction in men with HIV infection. Int J STD
AIDS 2006, 17:764-767.
22. Godin G, Cote J, Naccache H, Lambert LD, Trottier S: Prediction of
adherence to antiretroviral therapy: a one-year longitudinal study. AIDS
Care 2005, 17:493-504.
23. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL: Patterns,
correlates, and barriers to medication adherence among persons
prescribed new treatments for HIV disease. Health Psychol 2000,
19:124-133.
24. Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF: Factors
associated with adherence to antiretroviral medication in HIV-infected
patients. Int J STD AIDS 2002, 13:301-310.
25. Kalichman SC, Rompa D: HIV treatment adherence and unprotected sex
practices in people receiving antiretroviral therapy. Sex Transm Infect
2003, 79:59-61.
26. Baggaley RF, Ferguson NM, Garnett GP: The epidemiological impact of
antiretroviral use predicted by mathematical models: a review. Emerg
Themes Epidemiol 2005, 2:9.
27. Garnett GP, Garcia-Calleja JM, Rehle T, Gregson S: Behavioural data as an
adjunct to HIV surveillance data. Sex Transm Infect 2006, 82(Suppl 1):i57-i62.
28. Zaba B, Slaymaker E, Urassa M, Boerma JT: The role of behavioral data in
HIV surveillance. AIDS 2005, 19(Suppl 2):S39-S52.
29. Crepaz N, Hart TA, Marks G: Highly active antiretroviral therapy and
sexual risk behavior: a meta-analytic review. JAMA 2004, 292:224-236.
30. Kennedy C, O’Reilly K, Medley A, Sweat M: The impact of HIV treatment
on risk behaviour in developing countries: a systematic review. AIDS Care
2007, 19:707-720.
31. McClelland RS, Graham SM, Richardson BA, Peshu N, Masese LN, Wanje GH,
Mandaliya KN, Kurth AE, Jaoko W, Ndinya-Achola JO: Treatment with
antiretroviral therapy is not associated with increased sexual risk
behavior in Kenyan female sex workers. AIDS 2010, 24:891-897.
32. Venkatesh KK, de Bruyn G, Lurie MN, Mohapi L, Pronyk P, Moshabela M,
Marinda E, Gray GE, Triche EW, Martinson NA: Decreased sexual risk
behavior in the era of HAART among HIV-infected urban and rural
South Africans attending primary care clinics. AIDS 2010, 24:2687-2696.
33. Eisele TP, Mathews C, Chopra M, Lurie MN, Brown L, Dewing S, Kendall C:
Changes in risk behavior among HIV-positive patients during their first
year of antiretroviral therapy in Cape Town South Africa. AIDS Behav
2009, 13:1097-1105.
34. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W,
Coutinho A, Liechty C, Madraa E, Rutherford G, et al: Changes in sexual
behavior and risk of HIV transmission after antiretroviral therapy and
prevention interventions in rural Uganda. AIDS 2006, 20:85-92.
35. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML: Retention in HIV care for
individuals not yet eligible for antiretroviral therapy: rural KwaZulu-
Natal, South Africa. J Acquir Immune Defic Syndr 2010.
36. Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W,
Newell C, Viljoen J, Mutevedzi T, Newell ML: Cohort Profile: Africa Centre
Demographic Information System (ACDIS) and population-based HIV
survey. Int J Epidemiol 2008, 37:956-962.
37. Welz T, Hosegood V, Jaffar S, Bätzing-Feigenbaum J, Herbst K, Newell M:
Continued very high prevalence of HIV infection in rural KwaZulu-Natal,
South Africa: a population-based longitudinal study. AIDS 2007,
21:1467-1472.
38. Barnighausen T, Tanser F, Mbizana C, Gqwede Z, Herbst K, Newell ML: High
HIV incidence despite high prevalence in rural South Africa: findings
from a prospective population-based study. AIDS 2008, 22:139-144.
39. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, Newell ML:
Scale-up of a decentralized HIV treatment programme in rural KwaZulu-
Natal, South Africa: does rapid expansion affect patient outcomes? Bull
World Health Organ 2010, 88:593-600.
40. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H,
Newell ML: Cohort Profile: Hlabisa HIV Treatment and Care Programme.
Int J Epidemiol 2010.
41. HIV diagnosis at CD4 count above 500 cells/mm3 and progression to
below 350 cells/mm3 without antiretroviral therapy. J Acquir Immune
Defic Syndr 2007, 46:275-278.
42. Luppi P: How immune mechanisms are affected by pregnancy. Vaccine
2003, 21:3352-3357.
43. Cooper D, Harries J, Myer L, Orner P, Bracken H, Zweigenthal V: “Life is still
going on": reproductive intentions among HIV-positive women and men
in South Africa. Soc Sci Med 2007, 65:274-283.
44. Pronyk PM, Harpham T, Morison LA, Hargreaves JR, Kim JC, Phetla G,
Watts CH, Porter JD: Is social capital associated with HIV risk in rural
South Africa? Soc Sci Med 2008, 66:1999-2010.
45. Myer L, Stein DJ, Grimsrud A, Seedat S, Williams DR: Social determinants of
psychological distress in a nationally-representative sample of South
African adults. Soc Sci Med 2008, 66:1828-1840.
McGrath et al. BMC Public Health 2011, 11:121
http://www.biomedcentral.com/1471-2458/11/121
Page 8 of 9
46. Pulerwitz J, Barker G: Measuring attitudes towards gender norms among
young men in Brazil. Development and psychometric evaluation of the
GEM scale. Men and Masculinities 2008, 10:322-338.
47. Sayles JN, Hays RD, Sarkisian CA, Mahajan AP, Spritzer KL, Cunningham WE:
Development and psychometric assessment of a multidimensional
measure of internalized HIV stigma in a sample of HIV-positive adults.
AIDS Behav 2008, 12:748-758.
48. Boerma JT, Weir SS: Integrating demographic and epidemiological
approaches to research on HIV/AIDS: the proximate-determinants
framework. J Infect Dis 2005, 191(Suppl 1):S61-S67.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/121/prepub
doi:10.1186/1471-2458-11-121
Cite this article as: McGrath et al.: Design and methods of a
longitudinal study investigating the impact of antiretroviral treatment
on the partnerships and sexual behaviour of HIV-infected individuals in
rural KwaZulu-Natal, South Africa. BMC Public Health 2011 11:121.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McGrath et al. BMC Public Health 2011, 11:121
http://www.biomedcentral.com/1471-2458/11/121
Page 9 of 9
